Kumiva Group, LLC v. Garda USA Inc.

2017 NY Slip Op 235, 146 A.D.3d 504, 45 N.Y.S.3d 410
CourtAppellate Division of the Supreme Court of the State of New York
DecidedJanuary 12, 2017
Docket1818 650386/08
StatusPublished
Cited by15 cases

This text of 2017 NY Slip Op 235 (Kumiva Group, LLC v. Garda USA Inc.) is published on Counsel Stack Legal Research, covering Appellate Division of the Supreme Court of the State of New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kumiva Group, LLC v. Garda USA Inc., 2017 NY Slip Op 235, 146 A.D.3d 504, 45 N.Y.S.3d 410 (N.Y. Ct. App. 2017).

Opinion

Order, Supreme Court, New York County (Saliann Scarpulla, J.), entered August 5, 2015, which, insofar as appealed from as limited by the briefs, granted plaintiff/counterclaim defendant Kumiva Group, LLC (Kumiva) and counterclaim defendants Richard Irvin and Robert Irvin’s (Irvin defendants) motion for summary judgment dismissing defendant/counterclaim plaintiff Garda USA Inc. (Garda) and counterclaim plaintiff ATI Systems International, Inc.’s (ATI) counterclaim for fraud, and awarded Kumiva prejudgment interest, at the statutory rate, upon $6,250,000 of Garda’s liability, unanimously affirmed, with costs.

Garda is an American subsidiary of Garda World Security Corp., a Canadian corporation that is one of the largest security *505 and cash handling businesses in the world. Garda sought to expand its operations into the United States, and in 2006 approached the Irvin defendants, who controlled ATI, a private security and armored car company with large operations in the United States, about a potential acquisition. Concurrent to ATI’s negotiations with Garda, on November 30, 2006, ATI acquired CDC Systems Inc. (CDC), a smaller security and armored car company with a strong presence in the New York City market, for $25,000,000. ATI believed it could achieve significant synergies and cost savings by merging CDC’s New Jersey operations with ATI’s existing New Jersey operations.

On December 8, 2006, ATI counter-signed a nonbinding letter of intent from Garda, under which ATI agreed that Garda would conduct due diligence before purchasing ATI, and proposed that Garda would value ATI at 8.5 times ATI’s 2006 pro forma Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA). The letter of intent assumed a minimum 2006 pro forma EBITDA of $37,000,000, which would lead to a purchase price of $314,000,000, and established a maximum purchase price of $398,500,000 if ATI’s 2006 proforma EBITDA exceeded $45,000,000. Subsequently, Garda retained PricewaterhouseCoopers (PWC) to conduct due diligence along with Garda’s chief financial officer and investment bankers. Upon the conclusion of Garda’s due diligence, on February 25, 2007, Garda and ATI entered into an Agreement and Plan of Merger (the merger agreement) under which Garda agreed to acquire ATI for a purchase price of $341,700,000.

From December 8, 2006, when ATI countersigned Garda’s letter of intent, through February 25, 2007, when Garda and ATI entered into the merger agreement, the events forming the basis for the instant action occurred. During this period, Garda and ATI engaged in extensive negotiations, including numerous phone conferences, email exchanges, and meetings, to determine ATI’s 2006 pro-forma EBITDA and the purchase price for ATI. A major point of contention was the effect that the anticipated positive synergies and savings from ATI’s acquisition of CDC would have on ATI’s 2007 pro forma EBITDA.

Garda avers that approximately one third of ATI’s $341,700,000 purchase price was based on ATI’s representation to Garda of the value and positive synergies that ATI would realize through the integration of CDC into ATI’s operations. Garda accuses ATI of fraudulently inducing Garda to raise its offer by misrepresenting to Garda that ATI was achieving *506 significant savings by integrating CDC into its own operations, while minimizing the difficulties ATI was experiencing integrating CDC. Garda asserts that if it had known the extent of the difficulties ATI experienced integrating CDC, and the number of customers ATI lost due to these difficulties, Garda would have lowered its offer by an amount in the range from $36,000,000 to $81,000,000.

ATI acknowledges that it experienced significant issues integrating CDC, including a number of account cancellations due to unsatisfactory service. In fact, ATI insisted on including a disclosure in the merger agreement disclosing that ATI’s integration of CDC involved “several start-up issues including deposits being misrouted, lost or delayed, which caused some financial losses and some potential lost business.” Based on this disclosure and the due diligence Garda was allowed to conduct, Kumiva and the Irvin defendants assert that Garda had sufficient notice during the due diligence period of ATI’s difficulties integrating CDC and, notwithstanding such notice, agreed to the $341,700,000 purchase price.

As relevant to this appeal, Kumiva and the Irvin defendants moved for summary judgment dismissing Garda’s counterclaim for fraudulent inducement on the grounds that Garda failed to show “out of pocket” damages and justifiable reliance on ATI’s representations. Supreme Court granted Kumiva and the Irvin defendants summary judgment dismissing the fraudulent inducement counterclaims, holding that, as a matter of law, Garda failed to show nonspeculative damages and, further, that ATI’s disclosures precluded Garda from showing justifiable reliance. Upon Garda’s appeal, we affirm.

Initially, as to Garda’s damages, New York courts for over 100 years have differentiated between the damages recoverable for a breach of contract action and those recoverable for fraudulent inducement. While a plaintiff alleging breach of contract is entitled to damages restoring the full benefit of the bargain, a plaintiff alleging fraudulent inducement is limited to “out of pocket” damages, which consist solely of the actual pecuniary loss directly caused by the fraudulent inducement. “Out of pocket” damages are calculated in three steps. First, the plaintiff must show the actual value of the consideration it received. Second, the plaintiff must prove that the defendant’s fraudulent inducement directly caused the plaintiff to agree to deliver consideration that was greater than the value of the received consideration. Finally, the difference between the value of the received consideration and the delivered consideration constitutes “out of pocket” damages (see Lama Holding *507 Co. v Smith Barney, 88 NY2d 413, 421-422 [1996]; Sager v Friedman, 270 NY 472, 481 [1936]; Reno v Bull, 226 NY 546, 552-553 [1919]; Connaughton v Chipotle Mexican Grill, Inc., 135 AD3d 535, 538-539 [1st Dept 2016]).

Here, to show nonspeculative damages, Garda was required to submit evidence establishing ATI’s actual value on February 25, 2007, the date of the execution of the merger agreement setting the purchase price for the company. Next, Garda had the burden to submit evidence that ATI’s misrepresentations directly caused Garda to agree to pay consideration to ATI that was greater than ATI’s actual value. The difference between these two sums would then constitute Garda’s out-of-pocket damages. Garda failed to come forward with such evidence.

In opposition to Kumiva’s and the Irvin defendants’ motion for summary judgment, Garda submitted, inter alia, the expert affidavit of J.T. Atkins, the head of an advisory firm specializing in mergers and acquisitions. Atkins explained that the conventional manner to appraise a business requires conducting three studies: (1) a comparable company analysis; (2) a precedent transaction analysis; and (3) a discounted cash flow analysis. The results of these three studies are then triangulated to determine the value of the business.

Garda concedes that it failed to conduct a formal valuation of ATI’s value on February 25, 2007.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Applestein v. Kleinhendler
E.D. New York, 2025
OCFBrook Holdings, LLC v. TKS Brooklyn Ctr. Holding, LLC
2024 NY Slip Op 51611(U) (New York Supreme Court, New York County, 2024)
Growbright Enters., Inc. v. Barski
2024 NY Slip Op 33462(U) (New York Supreme Court, New York County, 2024)
Globalx, Inc. v. Hogwarts Capital, LLC
2024 NY Slip Op 02094 (Appellate Division of the Supreme Court of New York, 2024)
Danco Enters., LLC v. Livexlive Media, Inc.
209 A.D.3d 428 (Appellate Division of the Supreme Court of New York, 2022)
VXI Lux Holdco, S.A.R.L. v. SIC Holdings, LLC
2021 NY Slip Op 03294 (Appellate Division of the Supreme Court of New York, 2021)
Kaushal v. Singh
Appellate Terms of the Supreme Court of New York, 2017

Cite This Page — Counsel Stack

Bluebook (online)
2017 NY Slip Op 235, 146 A.D.3d 504, 45 N.Y.S.3d 410, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kumiva-group-llc-v-garda-usa-inc-nyappdiv-2017.